Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Amount
- Program total $5.5M
- Closes
- Oct 11, 2026 (in 29 days)
Similar opportunities open now
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
- Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses in 18 days
- Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Nov 2028
Classification and identifiers
- Solicitation number
- RFA-MH-27-135
- Assistance listing (CFDA)
- 93.242
Amount
Program total $5.5M
Who can apply
State government agencies, Private colleges and universities, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
About this opportunity
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.